+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

PRINTER FRIENDLY

Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2020

  • ID: 5024714
  • Drug Pipelines
  • April 2020
  • Region: Global
  • 403 pages
  • Global Markets Direct
1h Free Analyst Time

Speak directly to the analyst to clarify any post sales queries you may have.

1 of 3

FEATURED COMPANIES

  • 4SC AG
  • Biofrontera AG
  • Galderma SA
  • IO Biotech ApS
  • MediGene AG
  • NuCana Plc
  • MORE
Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline Review, H1 2020

Summary

This latest Pharmaceutical and Healthcare disease pipeline guide Basal Cell Carcinoma - Pipeline Review, H1 2020, provides an overview of the Basal Cell Carcinoma (Oncology) pipeline landscape.

Basal cell carcinoma is a type of skin cancer which begins in the basal cells. Symptoms include waxy bump, scaly, brown or flesh-colored patch and white, waxy scar. Predisposing factors include age, family history, and exposure to radiation and immunosuppressant medications. Treatment includes chemotherapy and surgery.

Report Highlights

This Pharmaceutical and Healthcare latest pipeline guide Basal Cell Carcinoma - Pipeline Review, H1 2020, provides comprehensive information on the therapeutics under development for Basal Cell Carcinoma (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Basal Cell Carcinoma (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I, Preclinical and Discovery stages are 3, 14, 8, 7 and 1 respectively.

Basal Cell Carcinoma (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the publisher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Basal Cell Carcinoma (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Basal Cell Carcinoma (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Basal Cell Carcinoma (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Basal Cell Carcinoma (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Basal Cell Carcinoma (Oncology)
Reasons to Buy
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Basal Cell Carcinoma (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Note: Product cover images may vary from those shown
2 of 3

FEATURED COMPANIES

  • 4SC AG
  • Biofrontera AG
  • Galderma SA
  • IO Biotech ApS
  • MediGene AG
  • NuCana Plc
  • MORE
  • Introduction
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Overview
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Development
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Therapeutics Assessment
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Companies Involved in Therapeutics Development
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Drug Profiles
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Product Development Milestones
  • Appendix
List of Tables
  • Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Products under Development by Companies, H1 2020
  • Products under Development by Companies, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Target, H1 2020
  • Number of Products by Stage and Target, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020
  • Number of Products by Stage and Mechanism of Action, H1 2020 (Contd..1), H1 2020
  • Number of Products by Stage and Route of Administration, H1 2020
  • Number of Products by Stage and Molecule Type, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by 4SC AG, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Adgero Biopharmaceuticals Holdings Inc, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Amgen Inc, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Bayer AG, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Biofrontera AG, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Biosceptre International Ltd, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Bristol-Myers Squibb Co, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Cannabis Science Inc, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Galderma SA, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Genentech Inc, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Invion Ltd, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by IO Biotech ApS, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Laboratories Ojer Pharma SL, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Leo Pharma AS, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Mayne Pharma Group Ltd, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by MediGene AG, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Medivir AB, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Merck & Co Inc, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by NuCana Plc, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Ono Pharmaceutical Co Ltd, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by PellePharm Inc, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Phosplatin Therapeutics LLC, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by QBiotics Ltd, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Regeneron Pharmaceuticals Inc, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Replimune Ltd, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Senhwa Biosciences Inc, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Sichuan Sinovation Bio-technology Co Ltd, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Singh Biotechnology LLC, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Pipeline by Transgene SA, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects, H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Dormant Projects, H1 2020 (Contd..1), H1 2020
  • Basal Cell Carcinoma (Basal Cell Epithelioma) - Discontinued Products, H1 2020
List of Figures
  • Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H1 2020
  • Number of Products under Development by Companies, H1 2020
  • Number of Products by Top 10 Targets, H1 2020
  • Number of Products by Stage and Top 10 Targets, H1 2020
  • Number of Products by Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Stage and Top 10 Mechanism of Actions, H1 2020
  • Number of Products by Top 10 Routes of Administration, H1 2020
  • Number of Products by Stage and Top 10 Routes of Administration, H1 2020
  • Number of Products by Molecule Types, H1 2020
  • Number of Products by Stage and Molecule Types, H1 2020
Note: Product cover images may vary from those shown
3 of 3

Loading
LOADING...

4 of 3
  • 4SC AG
  • Adgero Biopharmaceuticals Holdings Inc
  • Amgen Inc
  • Bayer AG
  • Biofrontera AG
  • Biosceptre International Ltd
  • Bristol-Myers Squibb Co
  • Cannabis Science Inc
  • Galderma SA
  • Genentech Inc
  • Guangdong Zhongsheng Pharmaceutical Co Ltd
  • Invion Ltd
  • IO Biotech ApS
  • Laboratories Ojer Pharma SL
  • Leo Pharma AS
  • Mayne Pharma Group Ltd
  • MediGene AG
  • Medivir AB
  • Merck & Co Inc
  • NuCana Plc
  • Ono Pharmaceutical Co Ltd
  • PellePharm Inc
  • Phosplatin Therapeutics LLC
  • QBiotics Ltd
  • Regeneron Pharmaceuticals Inc
  • Replimune Ltd
  • Senhwa Biosciences Inc
  • Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd
  • Sichuan Sinovation Bio-technology Co Ltd
  • Singh Biotechnology LLC
  • Transgene SA
Note: Product cover images may vary from those shown
Adroll
adroll